Peterlabs Holdings BhdXKLS:0171 +2.13%47 Current Ratio is 2.02 as of Jun. 2025, which is 27% below its 10-year median of 2.78. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100 and a GF Value™ of RM0.20 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 995 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks better than 50.95% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Peterlabs Holdings Bhd's current ratio for the quarter that ended in Jun. 2025 was 2.02.
Peterlabs Holdings Bhd has a current ratio of 2.02. It generally indicates good short-term financial strength.
The historical rank and industry rank for Peterlabs Holdings Bhd's Current Ratio or its related term are showing as below:
XKLS:0171'
s Current Ratio Range Over the Past 10 Years
Min: 2.02 Med: 2.78 Max: 4.32
Current: 2.02
During the past 13 years, Peterlabs Holdings Bhd's highest Current Ratio was 4.32. The lowest was 2.02. And the median was 2.78.
XKLS:0171's Current Ratio is ranked better than 50.95% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XKLS:0171: 2.02
Peterlabs Holdings Bhd (XKLS:0171) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Peterlabs Holdings Bhd Current Ratio Related Terms
Peterlabs Holdings Bhd Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0171 vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's Current Ratio distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a Current Ratio of 2.02 as of Jun. 2025. This is 27% below median its historical median of 2.78. Over the past decade, Peterlabs Holdings Bhd's Current Ratio has ranged from 2.02 to 4.32. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #488 out of 995 companies in the Drug Manufacturers industry, placing it in the top 49%.
Is Peterlabs Holdings Bhd's Current Ratio too high?
Peterlabs Holdings Bhd's current Current Ratio of 2.02 is 27% below median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 4.32. The Drug Manufacturers industry median Current Ratio is 2.00. Peterlabs Holdings Bhd's value of 2.02 is 1% above this industry median. Based on the distribution chart, Peterlabs Holdings Bhd ranks #488 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #488 out of 995 companies for Current Ratio. This puts Peterlabs Holdings Bhd in the upper half of its industry. The industry median Current Ratio is 2.00. Peterlabs Holdings Bhd's value of 2.02 is 1% above this benchmark. Historically, Peterlabs Holdings Bhd's own Current Ratio has ranged from 2.02 to 4.32 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 2.00, Peterlabs Holdings Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current Current Ratio of 2.02 is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current Current Ratio is 2.02, which is 27% below median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 20% above its estimated fair value. The current Current Ratio is 2.02, which is 27% below median its 10-year median of 2.78 and 1% above the Drug Manufacturers industry median of 2.00. Peterlabs Holdings Bhd's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current Current Ratio is 2.02 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued.
The current stock price of RM0.24 is trading 20% above its estimated GF Value™ of RM0.20.
GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0171:
Current Ratio: 2.02 (27% below median its 10-year median of 2.78)
GF Value™: RM0.20 vs. price of RM0.24 (20% above fair value)
Industry Position: 1% above the Drug Manufacturers median (#488 of 995)
No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
